Use of aceclofenac for the treatment of chronic pain in rheumatology
https://doi.org/10.14412/1996-7012-2018-1-66-72
Abstract
The high anti-inflammatory activity and pronounced analgesic effect of nonsteroidal anti-inflammatory drugs ((NSAIDs) allow successful treatment for pain syndrome associated with many diseases, primarily rheumatic diseases. NSAIDs are the main agents used to relieve pain in osteoarthritis, lower back pain, and periarticular soft tissue diseases. They are also an essential component of combination pharmacotherapy for chronic arthritis. The therapeutic effect of NSAIDs is determined by the suppressed activity of the cyclooxygenase (COX) isoenzymes COX- 1 and COX-2. The widely use of NSAIDs in clinical practice is considerably limited by the risk of adverse reactions (ARs) in the gastrointestinal tract (GIT), which are characteristic for this class of drugs. Medications that are able to selectively inhibit the activity of COX-2 while maintaining that of COX-1 less rarely cause ARs in GIT. This selective effect is produced by aceclofenac. A number of clinical trials have demonstrated the high efficacy of this drug in treating various locomotor diseases. The drug has been also noted to be well tolerated: the risk for aceclofenac- induced ARs in GIT is substantially lower than that due to the use of the majority of other NSAIDs.
About the Author
Yu. A. Olyunin
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
References
1. Каратеев АЕ. Неудовлетворенность лечением скелетно-мышечной боли: глобальная проблема и методы ее решения. Современная ревматология. 2017;11(3): 4–13. [Karateev AE. Dissatisfaction with management of musculoskeletal pain: A global problem and methods of its solution. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2017;11(3):4–13. (In Russ.)]. doi: 10.14412/1996-7012-2017-3-4-13
2. Зайцева ЕМ, Алексеева ЛИ. Причины боли при остеоартрозе и факторы прогрессирования заболевания (обзор литературы). Научно-практическая ревматология. 2011;49(1):50-7. [Zaitseva EM, Alekseeva LI. The causes of pain in osteoarthrosis and the factors of disease progression (a review of literature). Nauchno- prakticheskaya revmatologiya = Rheumatology Science and Practice. 2011;49(1):50-7. (In Russ.)]. doi: 10.14412/1995-4484-2011-867
3. Балабанова РМ. Остеоартроз или остеоартрит? Современное представление о болезни и ее лечении. Современная ревматология. 2013;7(3):67–70. [Balabanova RM. Osteoarthrosis or osteoarthritis? A current view of the disease and its treatment. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2013;7(3):67–70. (In Russ.)]. doi: 10.14412/1996-7012-2013-276
4. Авдеева АС. ИФНα-индуцируемый белок 10 (IP-10) при ревматоидном артрите: обзор литературы и собственные данные. Научно-практическая ревматология. 2017;55(6):655-61. [Avdeeva AS. IFN-α- induced protein 10 (IP-10) in rheumatoid arthritis: literature review and the authors' own data. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2017;55(6):655-61. (In Russ.)]. doi: 10.14412/1995-4484-2017-655-661
5. Насонов ЕЛ. Фармакотерапия ревматоидного артрита: российские и международные рекомендации. Научно-практическая ревматология. 2016;54(5):557- 71. [Nasonov EL. Pharmacotherapy for rheumatoid arthritis: russian and international guidelines. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2016;54(5):557-71. (In Russ.)]. doi: 10.14412/1995-4484-2016-557-571
6. Алексеева ЛИ, Зайцева ЕМ. Перспективные направления терапии остеоартроза. Научно-практическая ревматология. 2014;52(3):247–50. [Alekseeva LI, Zaitseva EM. Perspective directions of osteoarthritis therapy. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2014;52(3):247–50. (In Russ.)]. doi: 10.14412/1995-4484-2014-247-250
7. Kawahara K, Hohjoh H, Inazumi T, et al. Prostaglandin E2-induced inflammation: Relevance of prostaglandin E receptors. Biochim Biophys Acta. 2015 Apr;1851(4): 414-21. doi: 10.1016/j.bbalip.2014.07.008.
8. Каратеев АЕ. Ацеклофенак в ревматологии: «золотая середина». Современная ревматология. 2013;7(2):88-94. [Karateev AE. Aceclofenac in rheumatology: The golden mean. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2013;7(2):88-94. (In Russ.)]. Doi: 10.14412/1996-7012-2013-2389
9. Каратеев АЕ, Цурган АВ. Ацеклофенак: опыт российских исследований. Современная ревматология. 2017;11(4):89–94. [Karateev AE, Tsurgan AV. Aceclofenac: the experience of Russian studies. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2017;11(4):89–94. (In Russ.)]. doi: 10.14412/1996-7012-2017-4-89-94
10. Dahiya S, Kaushik A, Pathak K. Improved Pharmacokinetics of Aceclofenac Immediate Release Tablets Incorporating its Inclusion Complex with Hydroxypropyl-β- Cyclodextrin. Sci Pharm. 2015 Feb 2;83(3): 501-10. doi: 10.3797/scipharm.1509-07.
11. Kim E, Ihm C, Kang W. Modeling of aceclofenac metabolism to major metabolites in healthy volunteers. Drug Metab Pharmacokinet. 2016 Dec;31(6):458-463. doi: 10.1016/j.dmpk.2016.10.001.
12. Alvarez-Soria MA, Herrero-Beaumont G, Moreno-Rubio J, et al. Long-term NSAID treatment directly decreases COX-2 and mPGES-1 production in the articular cartilage of patients with osteoarthritis. Osteoarthritis Cartilage. 2008 Dec;16(12): 1484-93. doi: 10.1016/j.joca.2008.04.022.
13. Henrotin Y, de Leval X, Mathy-Hartet M, et al. In vitro effects of aceclofenac and its metabolites on the production by chondrocytes of inflammatory mediators. Inflamm Res. 2001 Aug;50(8):391-9.
14. Mastbergen SC, Jansen NW, Bijlsma JW, Lafeber FP. Differential direct effects of cyclo- oxygenase-1/2 inhibition on proteoglycan turnover of human osteoarthritic cartilage: an in vitro study. Arthritis Res Ther. 2006;8(1):R2
15. Blot L, Marcelis A, Devogelaer JP, Manicourt DH. Effects of diclofenac, aceclofenac and meloxicam on the metabolism of proteoglycans and hyaluronan in osteoarthritic human cartilage. Br J Pharmacol. 2000 Dec;131(7):1413-21.
16. Pareek A, Chandurkar N, Gupta A, et al. Efficacy and safety of aceclofenac-cr and aceclofenac in the treatment of knee osteoarthritis: a 6-week, comparative, randomized, multicentric, double-blind study. J Pain. 2011 May;12(5):546-53. doi: 10.1016/j.jpain.2010.10.013.
17. Batlle-Gualda E, Roman Ivorra J, Martin-Mola E, et al. Aceclofenac vs paracetamol in the management of symptomatic osteoarthritis of the knee: a double-blind 6- week randomized controlled trial. Osteoarthritis Cartilage. 2007 Aug;15(8):900-8.
18. Pareek A, Chandanwale AS, Oak J, et al. Efficacy and safety of aceclofenac in the treatment of osteoarthritis: a randomized double-blind comparative clinical trial versus diclofenac – an Indian experience. Curr Med Res Opin. 2006 May;22(5):977-88.
19. Moon YW, Kang SB, Kim TK, Lee MC. Efficacy and Safety of Aceclofenac Controlled Release in Patients with Knee Osteoarthritis: A 4-week, Multicenter, Randomized, Comparative Clinical Study. Knee Surg Relat Res. 2014 Mar;26(1):33-42. doi: 10.5792/ksrr.2014.26.1.33.
20. Pareek A, Chandurkar N, Sharma VD, et al. A randomized, multicentric, comparative evaluation of aceclofenac-paracetamol combination with aceclofenac alone in Indian patients with osteoarthritis flare-up. Expert Opin Pharmacother. 2009 Apr;10(5):727-35. doi: 10.1517/14656560902781931 .
21. Schattenkirchner M, Milachowski KA. A double-blind, multicentre, randomised clinical trial comparing the efficacy and tolerability of aceclofenac with diclofenac resinate in patients with acute low back pain. Clin Rheumatol. 2003 May;22(2):127-35.
22. Yang JH, Suk KS, Lee BH, et al. Efficacy and Safety of Different Aceclofenac Treatments for Chronic Lower Back Pain: Prospective, Randomized, Single Center, Open-Label Clinical Trials. Yonsei Med J. 2017 May;58(3):637-643. doi: 10.3349/ymj.2017.58.3.637.
23. Pareek A, Chandurkar N, Chandanwale AS, et al. Aceclofenac-tizanidine in the treatment of acute low back pain: a double-blind, double-dummy, randomized, multicentric, comparative study against aceclofenac alone. Eur Spine J. 2009 Dec;18(12): 1836-42. doi: 10.1007/s00586-009-1019-4.
24. Kumar S, Rani S, Siwach R, Verma P. To compare the efficacy and safety of fixed dose combination of thiocolchicoside and aceclofenac versus chlorzoxazone, aceclofenac and paracetamol in patients with acute lower backache associated with muscle spasm. Int J Appl Basic Med Res. 2014 Jul;4(2):101-5. doi: 10.4103/2229-516X.136789.
25. Добровольская ОВ, Торопцова НВ. Боль в спине и остеопороз: возможности симптоматического применения ацеклофенака. Клиническая фармакология и терапия. 2017;(2):1-8. [Dobrovol'skaya OV, Toroptsova NV. Back pain and osteoporosis: opportunities of symptomatic use of aceclofenac. Klinicheskaya farmakologiya i terapiya. 2017;(2):1-8. (In Russ.)].
26. Гонтаренко НВ, Цурган АВ, Каратеев АЕ. Лечение острой/подострой скелетно- мышечной боли с использованием алгоритма пошагового выбора назначения и контроля эффективности анальгетических средств. Предварительные данные программы АЛИСА (Анальгетическое Лечение с Использованием Системного Алгоритма). Современная ревматология. 2016;10(4):35–40. [Gontarenko NV, Tsurgan AV, Karateev AE. Treatment for acute/subacute musculoskeletal pain, by using an algorithm for stepwise choice of analgesic drugs and for monitoring their efficacy: preliminary data of the analgesic treatment using systemic algorithm (ATUSA) program. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2016;10(4):35–40. (In Russ.)]. doi: 10.14412/1996-7012-2016-4-35-40
27. Masso Gonzalez EL, Patrignani P, Tacconelli S, Garcia Rodriguez LA. Variability among nonsteroidal antiinflammatory drugs in risk of upper gastrointestinal bleeding. Arthritis Rheum. 2010 Jun;62(6): 1592-601. doi: 10.1002/art.27412
28. Castellsague J, Riera-Guardia N, Calingaert B, et al; Safety of Non-Steroidal Anti- Inflammatory Drugs (SOS) Project. Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project). Drug Saf. 2012 Dec 1;35(12): 1127-46. doi: 10.2165/11633470-000000000-00000
Review
For citations:
Olyunin YA. Use of aceclofenac for the treatment of chronic pain in rheumatology. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2018;12(1):66-72. (In Russ.) https://doi.org/10.14412/1996-7012-2018-1-66-72
Views:
880
Email this article 